ArticleFrontiers in oncology2019

Different Pathological Complete Response Rates According to PAM50 Subtype in HER2+ Breast Cancer Patients Treated With Neoadjuvant Pertuzumab/Trastuzumab vs. Trastuzumab Plus Standard Chemotherapy: An Analysis of Real-World Data.

Tamara Díaz-Redondo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.